WO2017063572A1 - Nouvelle forme cristalline d'agent induisant l'apoptose de cellules et son procédé de préparation - Google Patents

Nouvelle forme cristalline d'agent induisant l'apoptose de cellules et son procédé de préparation Download PDF

Info

Publication number
WO2017063572A1
WO2017063572A1 PCT/CN2016/102022 CN2016102022W WO2017063572A1 WO 2017063572 A1 WO2017063572 A1 WO 2017063572A1 CN 2016102022 W CN2016102022 W CN 2016102022W WO 2017063572 A1 WO2017063572 A1 WO 2017063572A1
Authority
WO
WIPO (PCT)
Prior art keywords
solvent
ray powder
powder diffraction
diffraction pattern
formula
Prior art date
Application number
PCT/CN2016/102022
Other languages
English (en)
Chinese (zh)
Inventor
陈敏华
张炎锋
陆飞
张晓宇
Original Assignee
苏州晶云药物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 苏州晶云药物科技有限公司 filed Critical 苏州晶云药物科技有限公司
Publication of WO2017063572A1 publication Critical patent/WO2017063572A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the invention relates to the field of chemical medicine, in particular to a novel crystal form of an apoptosis inducing agent and a preparation method thereof.
  • Apoptosis is the most basic biological process for multicellular organisms to maintain their structural stability and balance of internal environment functions and growth.
  • Apoptosis is a feature of escaping cancer.
  • One of the main ways by which cancer cells evade apoptosis is by up-regulating the anti-apoptotic proteins of the Bcl-2 family.
  • Bcl-2 protein In various cancers and conditions of the immune system, overexpression of Bcl-2 protein is associated with resistance to chemotherapy, clinical outcome, disease progression, overall prognosis, or a combination thereof.
  • Bcl-2 is involved in many hematological malignancies and is associated with poor prognosis in acute myeloid leukemia (AML). Patients with relapsed/refractory (R/R) AML usually have a poor prognosis and short survival.
  • ABT199 also known as Venetoclax, is a selective, potent, orally administered small molecule Bcl-2 inhibitor.
  • Venetoclax is a selective, potent, orally administered small molecule Bcl-2 inhibitor.
  • ABT199 The chemical name of ABT199 is 4-(4- ⁇ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl ⁇ piperazin-1-yl) -N-( ⁇ 3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl ⁇ sulfonyl)-2-(1H-pyrrolo[2,3-b Pyridine-5-yloxy)benzamide having the structural formula shown in Formula I.
  • the crystal form is known to be an important factor affecting the quality of the drug. Different crystal forms of the same drug may have significant differences in appearance, solubility, melting point, dissolution, bioavailability, etc., and may also have different effects on drug stability, bioavailability, and efficacy. Therefore, the development of new crystal forms that are more suitable for application is of great significance for drug development.
  • Example 5 of CN103153993A wherein the solid ABT199 obtained is amorphous.
  • CN103328474A discloses crystalline forms of ABT199 comprising 2 anhydrates, 2 hydrates and various solvates. Both the anhydrate and the hydrate in the patent are obtained by drying the solvate.
  • ABT199 is provided as a new anhydrate and hydrate form. These anhydrates and hydrates can be directly crystallized from a solvent, and have good stability, low wettability, and uniform particle size distribution, which are important for drug development.
  • the technical problem to be solved by the present invention is to overcome the deficiencies of the prior art and provide an anhydrate and a hydrate form of the compound of the formula (I) which can be directly decrystallized from a solvent, and are respectively named as crystal forms B and D of ABT199. F, G.
  • the present invention adopts the following technical solutions:
  • the invention provides crystal form B of ABT199, and its X-ray powder diffraction pattern at 25 ° C (CuK ⁇ radiation
  • the shot has a characteristic peak at a 2 ⁇ value of 5.3 ° ⁇ 0.2 °, 11.3 ° ⁇ 0.2 °, and 6.7 ° ⁇ 0.2 °.
  • the X-ray powder diffraction pattern of Form B also has characteristic peaks at one or more of 2 ⁇ values of 16.8° ⁇ 0.2°, 20.6° ⁇ 0.2°, 10.2° ⁇ 0.2°; preferably, the present invention
  • the X-ray powder diffraction pattern of Form B also has characteristic peaks at 2 ⁇ values of 16.8 ° ⁇ 0.2 °, 20.6 ° ⁇ 0.2 °, 10.2 ° ⁇ 0.2 °.
  • the X-ray powder diffraction pattern of Form B also has a characteristic peak at one or more of 2 ⁇ values of 15.7° ⁇ 0.2°, 5.9° ⁇ 0.2°, 22.8° ⁇ 0.2°; preferably, this
  • the X-ray powder diffraction pattern of Form B of the invention also has characteristic peaks at 2 ⁇ values of 15.7 ° ⁇ 0.2 °, 5.9 ° ⁇ 0.2 °, and 22.8 ° ⁇ 0.2 °.
  • said Form B has an X-ray powder diffraction pattern (CuK ⁇ radiation) at 25 ° C at a 2 ⁇ value of 5.3 ° ⁇ 0.2 °, 11.3 ° ⁇ 0.2 °, 6.7 ° ⁇ 0.2 Characteristic peaks are found in °, 16.8 ° ⁇ 0.2 °, 20.6 ° ⁇ 0.2 °, 10.2 ° ⁇ 0.2 °, 15.7 ° ⁇ 0.2 °, 5.9 ° ⁇ 0.2 °, and 22.8 ° ⁇ 0.2 °.
  • the X-ray powder diffraction pattern of Form B is as shown in FIG.
  • the crystalline form B provided by the present invention begins to exhibit an endothermic peak near heating to about 130 ° C, and the differential scanning calorimetry chart is substantially as shown in FIG.
  • the present invention provides Form B having a weight loss gradient of about 10.3% upon heating to 145 ° C, the thermogravimetric analysis of which is illustrated in FIG.
  • Another technical solution of the present invention provides a method for preparing ABT199 crystal form B, which comprises: placing a free form of ABT199 in an alkyl ether-based organic solvent, and obtaining a solid by stirring or volatilizing.
  • alkyl ether solvent is methyl tert-butyl ether.
  • the present invention provides Form D of ABT199 having an X-ray powder diffraction pattern (CuK ⁇ radiation) at 25 ° C having characteristic peaks at 2 ⁇ values of 12.7 ° ⁇ 0.2 °, 19.1 ° ⁇ 0.2 °, and 22.3 ° ⁇ 0.2 °.
  • the X-ray powder diffraction pattern of Form D is also at a 2 ⁇ value of 6.3 ° ⁇ 0.2 °, 16.8 ° ⁇ 0.2 °, One or more of 22.9 ° ⁇ 0.2 ° has a characteristic peak; preferably, the X-ray powder diffraction pattern of the crystalline form D of the present invention is also a 2 ⁇ value of 6.3 ° ⁇ 0.2 °, 16.8 ° ⁇ 0.2 °, 22.9 ° ⁇ There is a characteristic peak at 0.2°.
  • the X-ray powder diffraction pattern of Form D also has a characteristic peak at one or more of 2 ⁇ values of 11.4° ⁇ 0.2°, 16.4° ⁇ 0.2°, and 19.9° ⁇ 0.2°; preferably, this
  • the X-ray powder diffraction pattern of Form B of the invention also has characteristic peaks at 2 ⁇ values of 11.4 ° ⁇ 0.2 °, 16.4 ° ⁇ 0.2 °, and 19.9 ° ⁇ 0.2 °.
  • said Form D has an X-ray powder diffraction pattern (CuK ⁇ radiation) at 25 ° C at a 2 ⁇ value of 12.7 ° ⁇ 0.2 °, 19.1 ° ⁇ 0.2 °, 22.3 ° ⁇ 0.2 Characteristic peaks at °, 6.3 ° ⁇ 0.2 °, 16.8 ° ⁇ 0.2 °, 22.9 ° ⁇ 0.2 °, 11.4 ° ⁇ 0.2 °, 16.4 ° ⁇ 0.2 °, and 19.9 ° ⁇ 0.2 °.
  • the X-ray powder diffraction pattern of Form D is as shown in FIG.
  • the crystalline form D provided by the present invention begins to exhibit an endothermic peak near heating to 147 ° C, the differential scanning calorimetry diagram being substantially as shown in FIG.
  • the present invention provides Form D having a weight loss gradient of about 2.9% upon heating to 180 ° C, the thermogravimetric analysis of which is shown in FIG.
  • Another technical solution of the present invention is to provide a method for preparing ABT199 crystal form D, which comprises any one of the following methods:
  • ABT199 is placed in a mixed solvent of tetrahydrofuran and an anti-solvent, and the mixture is stirred to obtain a solid.
  • the anti-solvent includes, but is not limited to, one or more of water, an alkane, and an alkyl ether, preferably one or more of water, n-heptane, and methyl tert-butyl ether.
  • the present invention provides Form F of ABT199 having an X-ray powder diffraction pattern (CuK ⁇ radiation) at 25 ° C having characteristic peaks at 2 ⁇ values of 12.4 ° ⁇ 0.2 °, 13.3 ° ⁇ 0.2 °, and 5.9 ° ⁇ 0.2 °.
  • the X-ray powder diffraction pattern of Form F also has characteristic peaks at one or more of 2 ⁇ values of 17.5° ⁇ 0.2°, 18.5° ⁇ 0.2°, 19.0° ⁇ 0.2°; preferably, the present invention
  • the X-ray powder diffraction pattern of Form F also has characteristic peaks at 2 ⁇ values of 17.5 ° ⁇ 0.2 °, 18.5 ° ⁇ 0.2 °, and 19.0 ° ⁇ 0.2 °.
  • the X-ray powder diffraction pattern of Form F also has a characteristic peak at one or more of 2 ⁇ values of 21.3° ⁇ 0.2°, 24.2° ⁇ 0.2°, and 17.9° ⁇ 0.2°; preferably, The X-ray powder diffraction pattern of the inventive Form F also has characteristic peaks at 2 ⁇ values of 21.3 ° ⁇ 0.2 °, 24.2 ° ⁇ 0.2 °, and 17.9 ° ⁇ 0.2 °.
  • said Form F has an X-ray powder diffraction pattern (CuK ⁇ radiation) at 25 ° C at a 2 ⁇ value of 17.5 ° ⁇ 0.2 °, 13.3 ° ⁇ 0.2 °, 5.9 ° ⁇ 0.2 Characteristic peaks at °, 12.4 ° ⁇ 0.2 °, 18.5 ° ⁇ 0.2 °, 19.0 ° ⁇ 0.2 °, 21.3 ° ⁇ 0.2 °, 24.2 ° ⁇ 0.2 °, 17.9 ° ⁇ 0.2 °.
  • the X-ray powder diffraction pattern of Form F is as shown in FIG.
  • the crystalline form F provided by the present invention begins to exhibit an endothermic peak near heating to 210 ° C, the differential scanning calorimetry diagram being substantially as shown in FIG.
  • the present invention provides Form F having a weight loss gradient of about 4.8% upon heating to 200 ° C, the thermogravimetric analysis of which is shown in FIG.
  • Another technical solution of the present invention is to provide a method for preparing ABT199 crystal form F, which comprises any one of the following methods:
  • ABT199 is placed in a mixed solvent of acetic acid and water, and the mixture is stirred to obtain a solid.
  • the present invention provides a crystalline form G of ABT199 having an X-ray powder diffraction pattern (CuK ⁇ radiation) at 25 ° C having characteristic peaks at 2 ⁇ values of 10.6 ° ⁇ 0.2 °, 11.1 ° ⁇ 0.2 °, and 24.5 ° ⁇ 0.2 °.
  • the X-ray powder diffraction pattern of Form G also has characteristic peaks at one or more of 2 ⁇ values of 9.6° ⁇ 0.2°, 19.3° ⁇ 0.20°, 20.3° ⁇ 0.2°; preferably, the present invention
  • the X-ray powder diffraction pattern of Form G also has characteristic peaks at 2 ⁇ values of 9.6 ° ⁇ 0.2 °, 19.3 ° ⁇ 0.2 °, and 20.3 ° ⁇ 0.2 °.
  • the X-ray powder diffraction pattern of Form G has a characteristic peak at one or more of 2 ⁇ values of 11.8° ⁇ 0.2°, 14.6° ⁇ 0.2°, and 16.5° ⁇ 0.2°; preferably, this
  • the X-ray powder diffraction pattern of the inventive Form G also has characteristic peaks at 2 ⁇ values of 11.8 ° ⁇ 0.2 °, 14.6 ° ⁇ 0.2 °, and 16.5 ° ⁇ 0.2 °.
  • said Form G has an X-ray powder diffraction pattern (CuK ⁇ radiation) at 25 ° C at a 2 ⁇ value of 10.6 ° ⁇ 0.2 °, 11.1 ° ⁇ 0.2 °, 24.5 ° ⁇ 0.2 Characteristic peaks at °, 9.6 ° ⁇ 0.2 °, 19.3 ° ⁇ 0.2 °, 20.3 ° ⁇ 0.2 °, 11.8 ° ⁇ 0.2 °, 14.6 ° ⁇ 0.2 °, and 16.5 ° ⁇ 0.2 °.
  • CuK ⁇ radiation CuK ⁇ radiation
  • the X-ray powder diffraction pattern of Form G is as shown in FIG.
  • the crystalline form G provided by the present invention begins to exhibit an endothermic peak upon heating to around 185 ° C, the differential scanning calorimetry diagram being substantially as shown in FIG.
  • the present invention provides Form G having a weight loss gradient of about 4.4% upon heating to 200 ° C, the thermogravimetric analysis of which is illustrated in FIG.
  • Another technical solution of the present invention is to provide a method for preparing ABT199 crystal form G, which comprises any one of the following methods:
  • ABT199 is placed in a dioxane, an anti-solvent is added, and the solid is obtained by stirring to obtain a solid; or the free form of ABT199 is placed in a mixed solvent of dioxane and an anti-solvent, and the mixture is stirred to obtain a solid.
  • the anti-solvent includes, but is not limited to, one or more of water, alcohols, and aromatic hydrocarbons, preferably one or more of water, isopropanol, and toluene.
  • ABT199 is placed in acetic acid, an anti-solvent is added, and the solid is obtained by stirring; or the free form of ABT199 is placed in a mixed solvent of acetic acid and anti-solvent, and the solid is obtained by stirring.
  • the anti-solvent is one or more of an alcohol and an aromatic hydrocarbon, and preferably one or more of isopropanol and toluene.
  • ABT199 refers to the solid, semi-solid, wax or oil form of the compound of formula (I).
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of Form B or Form D or Form F or Form G or a mixture thereof in any ratio and a pharmaceutically acceptable pharmaceutical excipient.
  • a therapeutically effective amount of Form B or Form D or Form F or Form G or a mixture thereof in any ratio is mixed or contacted with one or more pharmaceutical excipients to form a pharmaceutical composition or formulation.
  • Pharmaceutical compositions or formulations are prepared in a manner well known in the pharmaceutical art.
  • the above pharmaceutical composition can be formulated into a certain dosage form and administered by a suitable route.
  • Dosage forms such as: solid oral preparations, including but not limited to such as powders, granules, pellets, tablets and capsules; liquid oral preparations including, but not limited to, syrups, suspensions, dispersions and emulsions And injections including, but not limited to, solutions, dispersing agents, and lyophilized formulations.
  • the dosage form may be immediate release, delayed release or slow release.
  • Release, and the immediate release preparation may be ordinary, dispersed, chewed, orally disintegrated or fast-dissolved; the sustained release preparation may form a skeleton or a reservoir system by hydrophilic or hydrophobic, or by a controlled release rate of hydrophilic and hydrophobic bonds. Or form a skeleton and reservoir system at the same time.
  • the formulation process may use, for example, direct pressure, dry granulation, wet granulation, and extrusion spheronization.
  • the formulations may be presented in a non-coating, film coating, sugar coating, powder coating, enteric or sustained release coating, and the like.
  • the route of administration is oral, parenteral (including subcutaneous, intramuscular, intravenous or intradermal), rectal, transdermal, nasal, vaginal and the like.
  • Dosage forms suitable for oral administration include tablets, capsules, granules, powders, pills, powders, lozenges, solutions, syrups or suspensions, which may be suitable for rapid release, delayed release or Regulating release;
  • dosage forms suitable for parenteral administration include aqueous or non-aqueous sterile injectable solutions, emulsions or suspensions; formulations suitable for rectal administration include suppositories or enemas; formulations suitable for transdermal administration include ointments, creams Agents, patches; dosage forms suitable for nasal administration include aerosols, sprays, nasal drops; dosage forms suitable for vaginal administration include suppositories, suppositories, gels, pastes or sprays.
  • formulations can be prepared by any method known in the art of pharmacy.
  • Routes of administration include oral, parenteral, sublingual, buccal, intranasal, pulmonary, topical, transdermal, intradermal, ocular, auricular, rectal, vaginal, intragastric, intracranial, intrasynovial or intra-articular. Route to give.
  • Form B or Form D or Form F or Form G or a mixture thereof in any ratio can be used to prepare a medicament for treating apoptosis dysfunction and/or overexpression related diseases of anti-apoptotic Bcl-2 family proteins Use in the formulation.
  • Form B or Form D or Form F or Form G or a mixture thereof in any ratio can be used for the preparation of a medicament for the treatment of an antitumor drug.
  • the invention provides a method of treating a disorder characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein, the method comprising administering to the patient a therapeutically effective amount of Form B or Form D Or a pharmaceutical composition of Form F or Form G or a mixture thereof in any ratio and a pharmaceutically acceptable pharmaceutical excipient.
  • the disease includes a tumor disease, an immune disease or an autoimmune disease, especially a tumor disease.
  • a tumor disease Including non-Hodgkin's lymphoma, chronic lymphoid leukemia or acute lymphocytic leukemia.
  • phrases "effective therapeutic amount” or “therapeutically effective amount” as used herein refers to a biological response or drug response that is caused by a researcher, veterinarian, doctor or other clinician in a tissue, system, animal, individual or human. The amount of active compound or agent.
  • treating refers to one or more of the following: (1) preventing a disease; for example, a disease or condition that may be predisposed to a disease, disorder, or disorder, but has not yet suffered or manifested the disease. Preventing the disease, condition or disorder in the individual; (2) inhibiting the disease; for example, inhibiting the disease, condition or disorder in an individual who is suffering from or showing a disease or condition of the disease, condition or disorder; and (3) improving the disease A disease; for example, ameliorating the disease, condition or disorder (i.e., reversing the disease and/or condition) in an individual suffering from or showing a disease or condition of the disease, condition or disorder, e.g., reducing the severity of the disease.
  • a disease for example, a disease or condition that may be predisposed to a disease, disorder, or disorder, but has not yet suffered or manifested the disease.
  • Preventing the disease, condition or disorder in the individual (2) inhibiting the disease; for example, inhibiting the disease, condition or disorder in an individual who is suffering from or
  • polymorph refers to different crystalline forms of the same compound and includes, but is not limited to, other solid molecular forms comprising hydrates and solvates of the same compound.
  • the phenomenon that a plurality of crystal forms are formed by the same drug molecule is called a drug polymorph, and a drug polymorph is a phenomenon commonly found in solid drugs. It is known that a pharmaceutical compound having such a polymorph has an influence on pharmacological activity, solubility, bioavailability, stability, and the like due to its physicochemical properties. Therefore, in the case where a compound which is useful as a drug has a polymorph, it is desirable to produce a crystal compound having high usefulness from these polymorphs.
  • X-ray powder diffraction pattern refers to an experimentally observed diffraction pattern or parameters derived therefrom.
  • the X-ray powder diffraction pattern was characterized by peak position and peak intensity.
  • the present invention has the following advantages compared with the prior art:
  • the invention unexpectedly discovered a new crystal form of ABT199, which has good stability, low wettability and uniform particle size distribution compared with the existing crystal form, and the crystal form can be directly crystallized in a solvent, and is contained.
  • the preparation of pharmaceutical preparations of ABT199 provides a new and better choice and is of great significance for drug development.
  • Figure 1 shows the XRPD pattern of ABT199 crystal form B.
  • Figure 2 is a DSC diagram of ABT199 crystal form B
  • FIG. 3 is a TGA diagram of ABT199 crystal form B
  • Figure 4 is a 1 H-NMR chart of Form A of ABT199
  • Figure 5 is an XRPD diagram of ABT199 crystal form D
  • FIG. 6 is a DSC diagram of ABT199 crystal form D
  • FIG. 7 is a TGA diagram of ABT199 crystal form D
  • Figure 8 is a 1 H-NMR chart of Form A of ABT199
  • Figure 9 is an XRPD diagram of ABT199 crystal form F
  • Figure 10 is a DSC diagram of ABT199 crystal form F
  • FIG. 11 is a TGA diagram of ABT199 crystal form F
  • Figure 12 is a 1 H-NMR chart of Form A of ABT199
  • Figure 13 is an XRPD diagram of ABT199 crystal form G
  • Figure 14 is a DSC diagram of the ABT199 crystal form G
  • Figure 15 is a TGA diagram of the ABT199 crystal form G
  • Figure 16 is a 1 H-NMR chart of Form A of ABT199
  • Figure 17 is a PLM diagram of anhydrate B of CN103328474A
  • Figure 18 is a PLM diagram of Form B of the present invention
  • Figure 19 is a PLM diagram of the crystal form D of the present invention
  • Figure 20 is a PLM diagram of the crystal form G of the present invention.
  • Figure 21 is an XRPD overlay before and after the grinding treatment (from the top to the bottom, the starting form F, the crystal form F after grinding, the anhydrous A in the starting CN103328474A and the anhydrate A in the ground CN103328474A after grinding) XRPD map)
  • test methods described are generally carried out under conventional conditions or conditions recommended by the manufacturer.
  • the X-ray powder diffraction pattern of the present invention was collected on a Panalytical Empyrean X-ray powder diffractometer.
  • the method parameters of the X-ray powder diffraction described in the present invention are as follows:
  • Scan range: from 3.0 to 40.0 degrees
  • the differential scanning calorimetry (DSC) map of the present invention was acquired on a TA Q2000.
  • the method parameters of the differential scanning calorimetry (DSC) described in the present invention are as follows:
  • thermogravimetric analysis (TGA) map of the present invention was taken on a TA Q5000.
  • the method parameters of the thermogravimetric analysis (TGA) described in the present invention are as follows:
  • the dynamic moisture adsorption (DVS) pattern of the present invention was collected on an Intrinsic dynamic moisture adsorber manufactured by SMS Corporation (Surface Measurement Systems Ltd.).
  • the method parameters of the dynamic moisture adsorber are as follows:
  • Relative humidity range 0%RH-95%RH
  • the particle size distribution test of the present invention uses a Microtrac S3500 laser particle size analyzer.
  • the Microtrac S3500 is equipped with an SDC (Sample Delivery Controller) injection system.
  • SDC Sample Delivery Controller
  • This test uses a wet method and the test dispersion medium is Isopar G. Set the test parameters according to the following table:
  • the polarizing microscope (PLM) pattern of the present invention was collected on an Axio Lab. A1 upright microscope manufactured by ZEISS.
  • ABT199 was weighed into a 20 mL glass vial, and 9 mL of methyl tert-butyl ether solvent was added dropwise, stirred at room temperature overnight, centrifuged, and the resulting solid was dried in vacuo.
  • the solid obtained in this example was Form B, and the X-ray powder diffraction data thereof is shown in Table 1.
  • the XRPD pattern is shown in Figure 1.
  • the DSC chart is shown in Figure 2.
  • An endothermic peak begins to appear near heating to 130 °C.
  • Its TGA pattern is shown in Figure 3 with a weight loss gradient of about 10.3% when heated to 145 °C.
  • 1 H-NMR is shown in Figure 4.
  • ABT199 14.7 mg was weighed into a 20 mL glass vial, dissolved in 14.0 mL of methyl t-butyl ether, and evaporated to give a solid at room temperature.
  • the solid obtained in this example was found to be Form B, and the X-ray powder diffraction data thereof is shown in Table 2.
  • ABT199 208.6 mg was weighed into a 20 mL glass vial, and 10 mL of a mixed solvent of tetrahydrofuran and water in a volume ratio of 1:2 was added thereto, stirred at 50 ° C overnight, and centrifuged to obtain a solid.
  • ABT199 24.9 mg was weighed into a 1.5 mL glass vial, dissolved in 0.1 mL of tetrahydrofuran, and 0.6 mL of the anti-solvent methyl tert-butyl ether was added dropwise, stirred at room temperature overnight, and centrifuged to obtain a solid.
  • ABT199 15.0 mg was weighed into a 1.5 mL glass vial, 0.2 mL of tetrahydrofuran was added thereto, 0.2 mL of anti-solvent water was added dropwise, and the mixture was stirred at 50 ° C overnight, and centrifuged to obtain a solid.
  • ABT199 14.8 mg was weighed into a 1.5 mL glass vial, 0.2 mL of acetic acid was added to dissolve, 0.2 mL of anti-solvent water was added dropwise, and the mixture was stirred at 50 ° C overnight, and centrifuged to obtain a solid.
  • the solid obtained in this example was found to be Form F, and its X-ray powder diffraction data is shown in Table 7.
  • the DSC chart is shown in Figure 10.
  • An endothermic peak begins to appear near 200 °C.
  • Its TGA pattern is shown in Figure 11, with a weight loss gradient of about 4.8% when heated to 200 °C.
  • the solid obtained in this example was found to be Form F, and its X-ray powder diffraction data is shown in Table 8. Its XRPD diagram is shown in Figure 9.
  • the solid obtained in this example was found to be crystalline form F, 1 H NMR as shown in Fig. 12, and X-ray powder diffraction data thereof are shown in Table 9.
  • ABT199 200.1 mg was weighed into a 20 mL glass vial, and 5 mL of a mixed solvent of acetic acid and toluene in a volume ratio of 1:49 was added thereto, stirred at room temperature overnight, and centrifuged to obtain a solid.
  • the solid obtained in this example was examined as Form G, and the X-ray powder diffraction data thereof is shown in Table 12. Its DSC chart is shown in Figure 14. An endothermic peak begins to appear near heating to 185 °C. Its TGA pattern is shown in Figure 15, with a weight loss gradient of about 4.4% when heated to 200 °C. 1 H NMR is shown in Figure 16.
  • each of the anhydrous B in CN103328474A, the crystalline form B of the present invention, the crystalline form D, the crystalline form F and the crystalline form G solid are placed at a constant temperature of 25 ° C / 60% RH and 40 ° C / 75% RH, respectively.
  • Samples were taken for the XRDD test at the initial placement and after the time shown in the table below. The results obtained are shown in Tables 13 and 14.
  • the crystal form B of the present invention According to the results of the long-term stability test and the accelerated stability test of Tables 13 and 14, the crystal form B of the present invention, the crystal form D, the crystal form F, and the form G were left unchanged for 9 months.
  • the anhydrate B has undergone crystal transformation in the 3-month long-term stability test and the 1-month accelerated stability test, and is converted into the hydrate C in CN103328474A. Therefore, the crystal forms B, D, G and F of the present invention exhibit better stability than the anhydrate B, and are more suitable for long-term storage and storage as a crystalline bulk drug or a drug, and are more developed and Practical value.
  • each of the anhydrous B of CN103328474A, the crystalline form B of the present invention, the crystalline form D, the crystalline form F and the crystalline form G solid sample were respectively subjected to DVS (Dynamic Moisture Absorption Test), and the results are shown in Table 15. According to the test results, the hygroscopicity of the crystalline form B, the crystalline form D, the crystalline form F and the crystalline form G of the present invention at 80% RH and 25 ° C was lower than that of the anhydrous B in CN103328474A.
  • Anhydrate B in CN103328474A is hygroscopic, and Form B and Form F of the present invention are slightly hygroscopic, and Form D and Form G are none. Or almost no wettability, and the crystal form B, the crystal form D, the form F and the form G of the present invention did not change in the DVS test. It can be seen that Form B, Form D, Form F and Form G have lower hygroscopicity than Anhydrate B in CN103328474A, and the stability is very good, suitable for later product development and storage. .
  • the wetting weight gain is not less than 15%
  • Humidity Wet weight gain is less than 15% but not less than 2%
  • wetting gain is less than 2% but not less than 0.2%
  • wetting gain is less than 0.2%
  • Mv represents the average particle size by volume
  • D10 indicates the particle size distribution (volume distribution) accounts for 10% of the particle size
  • D50 indicates the particle diameter corresponding to the particle size distribution (volume distribution), which is also called the median diameter.
  • D90 indicates the particle size distribution (volume distribution) accounts for 90% of the particle size
  • the crystal grains B, C and G of the present invention have an average particle diameter of about 20 ⁇ m and are normally distributed, and have a uniform particle dispersion property.
  • CN103328474A anhydrate B has different particle sizes, large differences, no normal distribution, and poor particle uniformity.
  • the polarized microscope sample test method is as follows: place about 0.5 mg of the sample onto the glass slide, add a small amount of mineral oil to disperse the sample, cover the cover slip and gently press with the fingertip to ensure that the slide and the cover slip are There are no bubbles at the tip. Adjust the eyepiece and objective of the microscope and fine tune the moving sample stage to focus on the sample.
  • CN103328474A Polarized light microscope (PLM) results for anhydrous B, Form B, Form D and Form G of the present invention are shown in Figures 17, 18, 19 and 20.
  • the solid morphology of the crystal form B, the crystal form D and the crystal form G of the present invention are also fine rods and uniform distribution, while the CN103328474A anhydrate B has obvious agglomeration and agglomeration.
  • the particle properties of the crystal form D and the crystal form G are not easily agglomerated or agglomerated, and the crystal morphology is regular.
  • the crystal form B, the crystal form D and the crystal form G of the present invention Compared with CN103328474A anhydrate B, it has a more uniform particle size distribution and a more regular crystal morphology, which helps to improve the performance of the drug during the process, and simplifies the post-treatment process such as powder homogenization. Drug development offers better options.
  • the crystal form F of the present invention and the anhydrous substance A of CN103328474A were each about 20 mg, respectively, and manually ground for 5 minutes in a mortar, and the sample XRPD test was performed before and after the grinding.
  • the test results are shown in Fig. 21. It can be seen that the crystal form F of the present invention has a decreased crystallinity after grinding, but the crystallinity is not lost, and the CN103328474A anhydrate A has been subjected to grinding and the test result is amorphous. It can be seen that the crystalline form F of the present invention has better mechanical grinding resistance than the anhydrous A in CN103328474A, so that it can maintain good stability and reliability during the post-treatment of tablets and the like.
  • the crystal form B of the present invention and the CN103328474A anhydrate A solid were each mixed 5 mg.
  • different water activities were set, and the stirring test at room temperature was carried out. After stirring overnight, the crystal form was examined, and it was found that crystal form B was obtained under the other water activities except that the mixture was stirred in pure water to obtain an amorphous shape. It can be seen that the crystal form B of the present invention can stably exist under various water activity conditions, and is suitable for later development.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une nouvelle forme cristalline d'un agent induisant l'apoptose de cellules et son procédé de préparation, la formule développée de cette dernière étant tel qu'indiqué dans la formule (I). Ces cristaux peuvent être obtenus directement à partir du solvant par cristallisation, et présentent une bonne stabilité, un faible mouillage et une distribution uniforme de la taille des particules, et procurent un nouveau choix, meilleur, pour la préparation de préparations pharmaceutiques contenant de l'ABT199, et sont d'une grande importance pour la mise au point de médicaments.
PCT/CN2016/102022 2015-10-13 2016-10-13 Nouvelle forme cristalline d'agent induisant l'apoptose de cellules et son procédé de préparation WO2017063572A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510660719 2015-10-13
CN201510660719.2 2015-10-13

Publications (1)

Publication Number Publication Date
WO2017063572A1 true WO2017063572A1 (fr) 2017-04-20

Family

ID=58517100

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2016/102022 WO2017063572A1 (fr) 2015-10-13 2016-10-13 Nouvelle forme cristalline d'agent induisant l'apoptose de cellules et son procédé de préparation

Country Status (1)

Country Link
WO (1) WO2017063572A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201800003284A1 (it) * 2018-03-05 2019-09-05 Olon Spa Forme cristalline di venetoclax
WO2020023435A1 (fr) 2018-07-24 2020-01-30 Albany Molecular Research, Inc. Sels basiques de vénétoclax et procédés de purification de vénétoclax
US11001582B2 (en) 2016-03-10 2021-05-11 Assia Chemical Industries Ltd. Solid state forms of Venetoclax and processes for preparation of Venetoclax
WO2021207581A1 (fr) * 2020-04-10 2021-10-14 Abbvie Inc. Formes cristallines d'un agent induisant l'apoptose

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010138588A2 (fr) * 2009-05-26 2010-12-02 Abbott Laboratories Agents induisant l'apoptose, dans le traitement du cancer et de maladies immunes et auto-immunes
WO2011150016A1 (fr) * 2010-05-26 2011-12-01 Abbott Laboratories Agents inducteurs d'apoptose pour le traitement du cancer et de maladies immunitaires et auto-immunes
WO2012071336A1 (fr) * 2010-11-23 2012-05-31 Abbott Laboratories Sels et formes cristallines d'un agent inducteur d'apoptose
CN104370905A (zh) * 2014-10-22 2015-02-25 南京友杰医药科技有限公司 Bcl-2抑制剂ABT-199的合成

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010138588A2 (fr) * 2009-05-26 2010-12-02 Abbott Laboratories Agents induisant l'apoptose, dans le traitement du cancer et de maladies immunes et auto-immunes
WO2011150016A1 (fr) * 2010-05-26 2011-12-01 Abbott Laboratories Agents inducteurs d'apoptose pour le traitement du cancer et de maladies immunitaires et auto-immunes
WO2012071336A1 (fr) * 2010-11-23 2012-05-31 Abbott Laboratories Sels et formes cristallines d'un agent inducteur d'apoptose
CN104370905A (zh) * 2014-10-22 2015-02-25 南京友杰医药科技有限公司 Bcl-2抑制剂ABT-199的合成

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11001582B2 (en) 2016-03-10 2021-05-11 Assia Chemical Industries Ltd. Solid state forms of Venetoclax and processes for preparation of Venetoclax
IT201800003284A1 (it) * 2018-03-05 2019-09-05 Olon Spa Forme cristalline di venetoclax
WO2019171222A1 (fr) * 2018-03-05 2019-09-12 Olon S.P.A. Formes cristallines de vénétoclax
WO2020023435A1 (fr) 2018-07-24 2020-01-30 Albany Molecular Research, Inc. Sels basiques de vénétoclax et procédés de purification de vénétoclax
WO2021207581A1 (fr) * 2020-04-10 2021-10-14 Abbvie Inc. Formes cristallines d'un agent induisant l'apoptose

Similar Documents

Publication Publication Date Title
TWI558704B (zh) 4-(8-甲氧基-1-(1-甲氧基丙-2-基)-2-(四氫-2H-吡喃-4-基)-1H-咪唑并[4,5-c]喹啉-7-基)-3,5-二甲基異噁唑及其用途
WO2017063572A1 (fr) Nouvelle forme cristalline d'agent induisant l'apoptose de cellules et son procédé de préparation
WO2018050091A1 (fr) Forme cristalline du chlorhydrate de l'ozanimod et son procédé de préparation
WO2018033149A1 (fr) Forme cristalline d'ozanimod et leur procédé de préparation
WO2017152707A1 (fr) Formes cristallines de sel de mésylate de dérivé de pyridinyl-aminopyrimidine, procédés de préparation et applications associés
WO2020063368A1 (fr) Forme cristalline d'un composé morpholino quinazoline, procédé de préparation associé et utilisation correspondante
WO2022170864A1 (fr) Forme cristalline du mésylate de beumosul, son procédé de préparation et son utilisation
WO2018157803A1 (fr) Formes cristallines de vénétoclax et leur procédé de préparation
WO2016155670A1 (fr) Inhibiteur de cdk, cristal eutectique d'inhibiteur de mek, et leur procédé de préparation
WO2016070697A1 (fr) Forme cristalline de bisulfate inhibiteur de kinase jak et procédé de préparation correspondant
WO2018006870A1 (fr) Forme cristalline de galunisertib, son procédé de préparation et son utilisation
WO2019228171A1 (fr) Sel d'un composé de pyrimidine à noyau condensé, sa forme cristalline, son procédé de préparation et son utilisation
WO2018086608A1 (fr) Forme cristalline d'antagoniste du récepteur de gnrh et son procédé de préparation
US20160046615A1 (en) Novel Crystal Form of Dabrafenib Mesylate and Preparation Method Thereof
WO2018133705A1 (fr) Forme cristalline de gft-505 et procédé de préparation et d'utilisation de celle-ci
WO2018072742A1 (fr) Forme cristalline de base libre de dérivé d'imidazo-isoindole et son procédé de préparation
WO2017162139A1 (fr) Cristal de sel de chlorhydrate d'un médicament pour le traitement ou la prévention de maladies associées à jak, et procédé de préparation de ce dernier
WO2016131406A1 (fr) Forme cristalline d'un inhibiteur oral des protéines kinases activées par des signaux mitogènes (mapk) et procédé de préparation de cette dernière
WO2023193563A1 (fr) Forme cristalline d'un composé thiénopyridine, son procédé de préparation et composition pharmaceutique associée
WO2019028689A1 (fr) Forme cristalline d'odm-201, son procédé de préparation et composition pharmaceutique correspondante
WO2019205812A1 (fr) Nouvelle forme cristalline de l'acalabrutinib, son procédé de préparation et son utilisation
WO2019210511A1 (fr) Sel d'addition de l'agoniste du récepteur s1p1, forme cristalline de celui-ci, et composition pharmaceutique
WO2018149309A1 (fr) Forme cristalline d'un dérivé de 4-phénylthiazole et son procédé de préparation
WO2018103027A1 (fr) Forme cristalline de tipifarnib, procédé de préparation et composition pharmaceutique associés
WO2021098716A1 (fr) Formes cristallines d'un composé cyclique fusionné, composition associée, leur procédé de préparation et leur utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16854948

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16854948

Country of ref document: EP

Kind code of ref document: A1